Fincantieri S.p.A.'s (BIT:FCT) P/S Is Still On The Mark Following 27% Share Price Bounce

The Fincantieri S.p.A. (BIT:FCT) share price has done very well over the last month, posting an excellent gain of 27%. The last 30 days were the cherry on top of the stock's 302% gain in the last year, which is nothing short of spectacular.

In spite of the firm bounce in price, there still wouldn't be many who think Fincantieri's price-to-sales (or "P/S") ratio of 0.7x is worth a mention when the median P/S in Italy's Machinery industry is similar at about 0.8x. Although, it's not wise to simply ignore the P/S without explanation as investors may be disregarding a distinct opportunity or a costly mistake.

Check out our latest analysis for Fincantieri

ps-multiple-vs-industry
BIT:FCT Price to Sales Ratio vs Industry August 31st 2025
Advertisement

How Fincantieri Has Been Performing

With revenue growth that's superior to most other companies of late, Fincantieri has been doing relatively well. Perhaps the market is expecting this level of performance to taper off, keeping the P/S from soaring. If not, then existing shareholders have reason to be feeling optimistic about the future direction of the share price.

Want the full picture on analyst estimates for the company? Then our free report on Fincantieri will help you uncover what's on the horizon.

What Are Revenue Growth Metrics Telling Us About The P/S?

Fincantieri's P/S ratio would be typical for a company that's only expected to deliver moderate growth, and importantly, perform in line with the industry.

If we review the last year of revenue growth, the company posted a terrific increase of 19%. As a result, it also grew revenue by 25% in total over the last three years. Accordingly, shareholders would have probably been satisfied with the medium-term rates of revenue growth.

Shifting to the future, estimates from the seven analysts covering the company suggest revenue should grow by 7.2% per year over the next three years. With the industry predicted to deliver 6.0% growth each year, the company is positioned for a comparable revenue result.

With this in mind, it makes sense that Fincantieri's P/S is closely matching its industry peers. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.

The Final Word

Its shares have lifted substantially and now Fincantieri's P/S is back within range of the industry median. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

We've seen that Fincantieri maintains an adequate P/S seeing as its revenue growth figures match the rest of the industry. Right now shareholders are comfortable with the P/S as they are quite confident future revenue won't throw up any surprises. All things considered, if the P/S and revenue estimates contain no major shocks, then it's hard to see the share price moving strongly in either direction in the near future.

Don't forget that there may be other risks. For instance, we've identified 2 warning signs for Fincantieri (1 is significant) you should be aware of.

If these risks are making you reconsider your opinion on Fincantieri, explore our interactive list of high quality stocks to get an idea of what else is out there.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About BIT:FCT

Fincantieri

Operates in the shipbuilding industry worldwide.

Solid track record with reasonable growth potential.

Advertisement

Weekly Picks

ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Looking to be second time lucky with a game-changing new product

Fair Value:US$21.5360.5% undervalued
135 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative
DE
Degen_GCR
P logo
Degen_GCR on Everpure ·

Second order memory play likely to double in a year

Fair Value:US$18053.1% undervalued
20 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
DO
Double_Bubbler
LUNR logo
Double_Bubbler on Intuitive Machines ·

Intuitive Machines: To The Moon and Beyond!

Fair Value:US$42.315.7% undervalued
11 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
YI
APP logo
yiannisz on AppLovin ·

AppLovin’s AI Engine Is Printing Profit

Fair Value:US$989.2454.2% undervalued
31 users have followed this narrative
2 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

QU
QuanD
AMD logo
QuanD on Advanced Micro Devices ·

Gaining Ground on Nvidia

Fair Value:US$274.3162.4% overvalued
42 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
MA
MarkoVT
5253 logo
MarkoVT on COVER ·

Significant headwinds will temper expectations for FY2027

Fair Value:JP¥2.28k36.9% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KA
kapirey
UNCY logo
kapirey on Unicycive Therapeutics ·

Unicycive Therapeutics is a late-stage clinical biotech transitioning toward commercialization

Fair Value:US$9.177.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

GO
QS logo
GoldenSands on QuantumScape ·

QuantumScape: A Mispriced Deep‑Tech Inflection Point With Multi‑Billion‑Dollar Optionality

Fair Value:US$8589.8% undervalued
108 users have followed this narrative
2 users have commented on this narrative
31 users have liked this narrative
KI
NVDA logo
Kingman1152 on NVIDIA ·

NVIDIA will see a profit margin surge of 55% in the next 5 years

Fair Value:US$305.226.0% undervalued
70 users have followed this narrative
2 users have commented on this narrative
24 users have liked this narrative
TR
tripledub
META logo
tripledub on Meta Platforms ·

The $135 Billion Bet That Should Make Every Shareholder Nervous

Fair Value:US$74016.7% undervalued
37 users have followed this narrative
3 users have commented on this narrative
33 users have liked this narrative